

Oregon HPV SUMMIT Jun. 11, 2019

Allison Naleway, PhD

Breakout Session 1 1:10-2:00 p.m.

HPV Safety and Effectiveness Research in an Integrated Healthcare Delivery System

Learning Objectives

 To provide participants with an understanding of HPV vaccine safety and effectiveness research being conducted in Oregon by Kaiser Permanente Northwest.

Summary

This presentation will describe the comprehensive HPV vaccine safety and effectiveness research conducted over the past decade at Kaiser Permanente Northwest, an integrated healthcare delivery system providing care to nearly 610,000 members in Oregon and Washington. We will summarize key findings from several completed HPV safety studies, including a recently-published study which found no increased risk of primary ovarian insufficiency after vaccination. We will describe several completed and on-going studies designed to assess HPV vaccine effectiveness for the prevention of anogenital warts in both females and males, and will discuss a long-term project in collaboration with the Centers for Disease Control and Prevention to monitor the impact of vaccination on HPV prevalence in residual liquid cytology specimens collected from young women undergoing routine cervical cancer screening.